scholarly journals Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease

Blood ◽  
2013 ◽  
Vol 122 (23) ◽  
pp. 3778-3783 ◽  
Author(s):  
Kelsie M. Bernot ◽  
John S. Nemer ◽  
Ramasamy Santhanam ◽  
Shujun Liu ◽  
Nicholas A. Zorko ◽  
...  

Key Points The MllPTD/wt:Flt3ITD/wt mouse is a relevant AML model in which the miR-29b–mediated epigenetics-kinome crosstalk is targetable by bortezomib. An original liposomal formulation of bortezomib eradicates AML and yields curative therapy for MllPTD/wt:Flt3ITD/wt AML.

Blood ◽  
2015 ◽  
Vol 125 (15) ◽  
pp. 2386-2396 ◽  
Author(s):  
Francis Mussai ◽  
Sharon Egan ◽  
Joseph Higginbotham-Jones ◽  
Tracey Perry ◽  
Andrew Beggs ◽  
...  

Key Points Arginase depletion with BCT-100 pegylated recombinant human arginase is cytotoxic to AML blasts.


Blood ◽  
2013 ◽  
Vol 122 (7) ◽  
pp. 1316-1324 ◽  
Author(s):  
Margaret L. Green ◽  
Wendy M. Leisenring ◽  
Hu Xie ◽  
Roland B. Walter ◽  
Marco Mielcarek ◽  
...  

Key Points CMV reactivation after HCT is associated with a reduced risk of early relapse in patients with AML but not other disease groups. The benefit, however, is offset by an increased risk of nonrelapse mortality.


Blood ◽  
2017 ◽  
Vol 129 (6) ◽  
pp. 771-782 ◽  
Author(s):  
Jason A. Powell ◽  
Alexander C. Lewis ◽  
Wenying Zhu ◽  
John Toubia ◽  
Melissa R. Pitman ◽  
...  

Key Points Inhibition of SPHK1 in human AML cells induces MCL1 degradation and caspase-dependent cell death. SPHK1 inhibitors reduce leukemic burden and prolong survival in orthotopic patient-derived xenografts of AML.


Blood ◽  
2016 ◽  
Vol 128 (14) ◽  
pp. 1854-1861 ◽  
Author(s):  
Eduard J. Libourel ◽  
Clara P. W. Klerk ◽  
Yvette van Norden ◽  
Moniek P. M. de Maat ◽  
Marieke J. Kruip ◽  
...  

Key Points A high D-dimer level strongly predicts symptomatic venous and arterial thrombosis in newly diagnosed AML. Thrombosis occurs in up to 10% of patients with newly diagnosed AML.


Blood ◽  
2016 ◽  
Vol 127 (11) ◽  
pp. 1449-1458 ◽  
Author(s):  
Weiwei Shen ◽  
Mrinal M. Patnaik ◽  
Autumn Ruiz ◽  
Stephen J. Russell ◽  
Kah-Whye Peng

Key Points IV therapy with oncolytic VSV-IFNβ-NIS virus extends survival of immunocompetent mice with AML. The therapeutic outcome of VSV-IFNβ-NIS–treated mice with AML is augmented by anti-PD-L1 immunotherapy.


Author(s):  
Meredith Beaton, RN, MSN, AG-ACNP ◽  
Glen J. Peterson, RN, DNP, ACNP ◽  
Kelly O'Brien, RN, MSN, ANP-C, ACNP-BC

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, diagnosed in approximately 21,450 individuals annually in the US with nearly 11,000 deaths attributable to this disease (National Cancer Institute, 2020). Acute myeloid leukemia is a disease of the elderly, with the average age of diagnosis being 68 years old (Kouchkovsky & Abdul-Hay, 2016). It is a heterogeneous disease with widely varying presentations but universally carries a poor prognosis in the majority of those affected. Unfortunately, the 5-year overall survival rate remains poor, at less than 5% in patients over 65 years of age (Thein, Ershler, Jemal, Yates, & Baer, 2013). The landscape of AML is beginning to change, however, as new and improved treatments are emerging. Advanced practitioners (APs) are often involved in the care of these complex patients from the time of initial symptoms through diagnosis, treatment, and potentially curative therapy. It is vitally important for APs to understand and be aware of the various presentations, initial management strategies, diagnostic workup, and treatment options for patients with AML, especially in the elderly population, which until recently had few treatment options. This Grand Rounds article highlights the common presenting signs and symptoms of patients with AML in the hospital, including a discussion of the upfront clinical stability issues, oncologic emergencies, diagnostic evaluation, and current treatment options for elderly patients and those with poor performance status.


2021 ◽  
Vol 5 (7) ◽  
pp. 2012-2016
Author(s):  
Reine El Omar ◽  
Emmanuelle Julien ◽  
Katia Biasch ◽  
Blandine Guffroy ◽  
Bruno Lioure ◽  
...  

Key Points Expression of caudal-related homeobox gene 2 (CDX2) and angiotensin-converting enzyme (ACE) correlates during hematopoietic emergence. This emergence occurs in human and mouse embryos and in human acute myeloid leukemia; CDX2 homeoprotein also binds to the ACE promoter.


Blood ◽  
2014 ◽  
Vol 123 (5) ◽  
pp. 734-742 ◽  
Author(s):  
Suiyang Liu ◽  
Li Yin ◽  
Dina Stroopinsky ◽  
Hasan Rajabi ◽  
Alexandre Puissant ◽  
...  

Key Points The MUC1-C oncoprotein is aberrantly expressed in AML cells and contributes to activation of the mutant FLT3 receptor. Targeting MUC1-C thus inhibits FLT3 signaling and represents a potential approach for AML cells resistant to FLT3 inhibitors.


2018 ◽  
Vol 2 (16) ◽  
pp. 2095-2103 ◽  
Author(s):  
Mary Eapen ◽  
Ruta Brazauskas ◽  
Michael Hemmer ◽  
Waleska S. Perez ◽  
Patricia Steinert ◽  
...  

Key Points Bu4/Cy, Flu/Bu4, and Flu/Mel are optimal regimens for patients with AML in clinical remission or those with MDS. Flu/Mel, considered a less-intense regimen, is ideal for less fit patients.


Sign in / Sign up

Export Citation Format

Share Document